PMID: 6540397Aug 1, 1984Paper

Chronic low-dose levodopa therapy in Parkinson's disease: an argument for delaying levodopa therapy

Neurology
A H RajputW H Laverty

Abstract

Levodopa is the most useful drug for treatment of Parkinson's disease today. But after continued use for several years, the effectiveness declines, and the undesirable side effects become more frequent, leading to unsatisfactory control. Once the treatment failure emerges, further management is difficult and often unsuccessful. One alternative for preventing side effects and treatment failure is to use a low dose. We are reporting our 12-year experience on uninterrupted treatment with levodopa, 3 grams (approximate) daily. The improvement was comparable with the best reports on higher dosage, and the side effects were significantly less frequent. The frequency of dyskinesia and on-off phenomena showed a strong correlation with duration of treatment. Psychiatric side effects were more common on treatment, but frequency of dementia did not correlate with duration of therapy. Improvement reached a peak after 6 months and remained statistically significant for 3.5 years. By the end of 5 years, the disability profile in the group was similar to that prior to levodopa treatment. So far, there is no satisfactory method for preventing treatment failure. From our observations, low dosage of levodopa is a desirable alternative, but not t...Continue Reading

Citations

Sep 24, 1999·Movement Disorders : Official Journal of the Movement Disorder Society·W J Weiner
May 1, 1990·Annals of Neurology·M W HorstinkM A van 't Hof
Apr 1, 1994·Annals of Neurology·A H RajputO Hornykiewicz
Mar 29, 2002·Movement Disorders : Official Journal of the Movement Disorder Society·Azi H RajputOleh Hornykiewicz
Dec 5, 2002·Movement Disorders : Official Journal of the Movement Disorder Society·Sam BirdiDavid George
Jun 8, 2001·Movement Disorders : Official Journal of the Movement Disorder Society·J E Ahlskog, M D Muenter
Jan 1, 1990·Movement Disorders : Official Journal of the Movement Disorder Society·S BoyceA R Crossman
Oct 1, 1992·Movement Disorders : Official Journal of the Movement Disorder Society·R E Burke
Apr 1, 1993·Movement Disorders : Official Journal of the Movement Disorder Society·U BonuccelliA Muratorio
Jul 1, 1993·Movement Disorders : Official Journal of the Movement Disorder Society·S A Factor, W J Weiner
Oct 1, 1993·Movement Disorders : Official Journal of the Movement Disorder Society·J JankovicJ C Goodman
May 1, 1997·Movement Disorders : Official Journal of the Movement Disorder Society·A RajputA H Rajput
Sep 26, 1997·Movement Disorders : Official Journal of the Movement Disorder Society·A H RajputR Macaulay
Oct 2, 1998·Movement Disorders : Official Journal of the Movement Disorder Society·A H RajputN Galvez-Jimenez
May 1, 1989·Journal of Neurology·S M Ludin, H P Ludin
Oct 3, 2001·Current Treatment Options in Neurology·Stewart A. Factor
Jan 1, 1987·Pharmacology & Therapeutics·A E Lang
Jan 1, 1994·Pharmacology & Therapeutics·M E GötzM B Youdim
May 4, 2004·Parkinsonism & Related Disorders·Ali H RajputOleh Hornykiewicz
Jun 7, 1986·Lancet·A H Rajput, R J Uitti
Mar 14, 1987·Lancet·C E ClarkeA R Crossman
Sep 5, 2001·Neurologic Clinics·J E Ahlskog
Aug 8, 2001·Parkinsonism & Related Disorders·A H Rajput
Jul 2, 2008·Parkinsonism & Related Disorders·A H Rajput, S Birdi
Jul 2, 2008·Parkinsonism & Related Disorders·A H RajputK P Offord
Oct 26, 1999·Gerodontology·T J CliffordP J Lamey
Mar 1, 1989·Journal of Neurology, Neurosurgery, and Psychiatry·M A HelyG A Broe
Mar 1, 1990·Journal of Neurology, Neurosurgery, and Psychiatry·M W HorstinkM A van't Hof
Aug 26, 1998·Reviews in the Neurosciences·E BezardC E Gross
Jul 30, 1999·Journal of the Neurological Sciences·A P Denny, M Behari
Aug 19, 1999·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·P J Blanchet
May 5, 1998·Molecular and Chemical Neuropathology·C S MyersG C Wagner
Feb 10, 2006·Expert Review of Neurotherapeutics·Alex Rajput, Ali H Rajput
Jul 21, 2015·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Leslie Wayne FergusonAlexander Rajput
Mar 7, 2003·Movement Disorders : Official Journal of the Movement Disorder Society·Frédéric CalonThérèse Di Paolo
Sep 12, 2008·Movement Disorders : Official Journal of the Movement Disorder Society·Cory TothDouglas Zochodne
Jul 11, 2006·Movement Disorders : Official Journal of the Movement Disorder Society·Vincent ChungMin Li
Jan 1, 2014·Movement Disorders : Official Journal of the Movement Disorder Society·Ali H Rajput
Nov 27, 2001·Biological Psychiatry·P K TekumallaE J Nestler
Jul 1, 1987·Annals of Neurology·G J de JongP I Schmitz

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.